Cargando…

Oral Vaccination of Free-Living Badgers (Meles meles) with Bacille Calmette Guérin (BCG) Vaccine Confers Protection against Tuberculosis

A field trial was conducted to investigate the impact of oral vaccination of free-living badgers against natural-transmitted Mycobacterium bovis infection. For a period of three years badgers were captured over seven sweeps in three zones and assigned for oral vaccination with a lipid-encapsulated B...

Descripción completa

Detalles Bibliográficos
Autores principales: Gormley, Eamonn, Ní Bhuachalla, Deirdre, O’Keeffe, James, Murphy, Denise, Aldwell, Frank E., Fitzsimons, Tara, Stanley, Paul, Tratalos, Jamie A., McGrath, Guy, Fogarty, Naomi, Kenny, Kevin, More, Simon J., Messam, Locksley L. McV., Corner, Leigh A. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266210/
https://www.ncbi.nlm.nih.gov/pubmed/28121981
http://dx.doi.org/10.1371/journal.pone.0168851
_version_ 1782500429140066304
author Gormley, Eamonn
Ní Bhuachalla, Deirdre
O’Keeffe, James
Murphy, Denise
Aldwell, Frank E.
Fitzsimons, Tara
Stanley, Paul
Tratalos, Jamie A.
McGrath, Guy
Fogarty, Naomi
Kenny, Kevin
More, Simon J.
Messam, Locksley L. McV.
Corner, Leigh A. L.
author_facet Gormley, Eamonn
Ní Bhuachalla, Deirdre
O’Keeffe, James
Murphy, Denise
Aldwell, Frank E.
Fitzsimons, Tara
Stanley, Paul
Tratalos, Jamie A.
McGrath, Guy
Fogarty, Naomi
Kenny, Kevin
More, Simon J.
Messam, Locksley L. McV.
Corner, Leigh A. L.
author_sort Gormley, Eamonn
collection PubMed
description A field trial was conducted to investigate the impact of oral vaccination of free-living badgers against natural-transmitted Mycobacterium bovis infection. For a period of three years badgers were captured over seven sweeps in three zones and assigned for oral vaccination with a lipid-encapsulated BCG vaccine (Liporale-BCG) or with placebo. Badgers enrolled in Zone A were administered placebo while all badgers enrolled in Zone C were vaccinated with BCG. Badgers enrolled in the middle area, Zone B, were randomly assigned 50:50 for treatment with vaccine or placebo. Treatment in each zone remained blinded until the end of the study period. The outcome of interest was incident cases of tuberculosis measured as time to seroconversion events using the BrockTB Stat-Pak lateral flow serology test, supplemented with post-mortem examination. Among the vaccinated badgers that seroconverted, the median time to seroconversion (413 days) was significantly longer (p = 0.04) when compared with non-vaccinated animals (230 days). Survival analysis (modelling time to seroconversion) revealed that there was a significant difference in the rate of seroconversion between vaccinated and non-vaccinated badgers in Zones A and C throughout the trial period (p = 0.015). For badgers enrolled during sweeps 1–2 the Vaccine Efficacy (VE) determined from hazard rate ratios was 36% (95% CI: -62%– 75%). For badgers enrolled in these zones during sweeps 3–6, the VE was 84% (95% CI: 29%– 97%). This indicated that VE increased with the level of vaccine coverage. Post-mortem examination of badgers at the end of the trial also revealed a significant difference in the proportion of animals presenting with M. bovis culture confirmed lesions in vaccinated Zone C (9%) compared with non-vaccinated Zone A (26%). These results demonstrate that oral BCG vaccination confers protection to badgers and could be used to reduce incident rates in tuberculosis-infected populations of badgers.
format Online
Article
Text
id pubmed-5266210
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-52662102017-02-17 Oral Vaccination of Free-Living Badgers (Meles meles) with Bacille Calmette Guérin (BCG) Vaccine Confers Protection against Tuberculosis Gormley, Eamonn Ní Bhuachalla, Deirdre O’Keeffe, James Murphy, Denise Aldwell, Frank E. Fitzsimons, Tara Stanley, Paul Tratalos, Jamie A. McGrath, Guy Fogarty, Naomi Kenny, Kevin More, Simon J. Messam, Locksley L. McV. Corner, Leigh A. L. PLoS One Research Article A field trial was conducted to investigate the impact of oral vaccination of free-living badgers against natural-transmitted Mycobacterium bovis infection. For a period of three years badgers were captured over seven sweeps in three zones and assigned for oral vaccination with a lipid-encapsulated BCG vaccine (Liporale-BCG) or with placebo. Badgers enrolled in Zone A were administered placebo while all badgers enrolled in Zone C were vaccinated with BCG. Badgers enrolled in the middle area, Zone B, were randomly assigned 50:50 for treatment with vaccine or placebo. Treatment in each zone remained blinded until the end of the study period. The outcome of interest was incident cases of tuberculosis measured as time to seroconversion events using the BrockTB Stat-Pak lateral flow serology test, supplemented with post-mortem examination. Among the vaccinated badgers that seroconverted, the median time to seroconversion (413 days) was significantly longer (p = 0.04) when compared with non-vaccinated animals (230 days). Survival analysis (modelling time to seroconversion) revealed that there was a significant difference in the rate of seroconversion between vaccinated and non-vaccinated badgers in Zones A and C throughout the trial period (p = 0.015). For badgers enrolled during sweeps 1–2 the Vaccine Efficacy (VE) determined from hazard rate ratios was 36% (95% CI: -62%– 75%). For badgers enrolled in these zones during sweeps 3–6, the VE was 84% (95% CI: 29%– 97%). This indicated that VE increased with the level of vaccine coverage. Post-mortem examination of badgers at the end of the trial also revealed a significant difference in the proportion of animals presenting with M. bovis culture confirmed lesions in vaccinated Zone C (9%) compared with non-vaccinated Zone A (26%). These results demonstrate that oral BCG vaccination confers protection to badgers and could be used to reduce incident rates in tuberculosis-infected populations of badgers. Public Library of Science 2017-01-25 /pmc/articles/PMC5266210/ /pubmed/28121981 http://dx.doi.org/10.1371/journal.pone.0168851 Text en © 2017 Gormley et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gormley, Eamonn
Ní Bhuachalla, Deirdre
O’Keeffe, James
Murphy, Denise
Aldwell, Frank E.
Fitzsimons, Tara
Stanley, Paul
Tratalos, Jamie A.
McGrath, Guy
Fogarty, Naomi
Kenny, Kevin
More, Simon J.
Messam, Locksley L. McV.
Corner, Leigh A. L.
Oral Vaccination of Free-Living Badgers (Meles meles) with Bacille Calmette Guérin (BCG) Vaccine Confers Protection against Tuberculosis
title Oral Vaccination of Free-Living Badgers (Meles meles) with Bacille Calmette Guérin (BCG) Vaccine Confers Protection against Tuberculosis
title_full Oral Vaccination of Free-Living Badgers (Meles meles) with Bacille Calmette Guérin (BCG) Vaccine Confers Protection against Tuberculosis
title_fullStr Oral Vaccination of Free-Living Badgers (Meles meles) with Bacille Calmette Guérin (BCG) Vaccine Confers Protection against Tuberculosis
title_full_unstemmed Oral Vaccination of Free-Living Badgers (Meles meles) with Bacille Calmette Guérin (BCG) Vaccine Confers Protection against Tuberculosis
title_short Oral Vaccination of Free-Living Badgers (Meles meles) with Bacille Calmette Guérin (BCG) Vaccine Confers Protection against Tuberculosis
title_sort oral vaccination of free-living badgers (meles meles) with bacille calmette guérin (bcg) vaccine confers protection against tuberculosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266210/
https://www.ncbi.nlm.nih.gov/pubmed/28121981
http://dx.doi.org/10.1371/journal.pone.0168851
work_keys_str_mv AT gormleyeamonn oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT nibhuachalladeirdre oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT okeeffejames oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT murphydenise oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT aldwellfranke oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT fitzsimonstara oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT stanleypaul oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT tratalosjamiea oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT mcgrathguy oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT fogartynaomi oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT kennykevin oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT moresimonj oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT messamlocksleylmcv oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis
AT cornerleighal oralvaccinationoffreelivingbadgersmelesmeleswithbacillecalmetteguerinbcgvaccineconfersprotectionagainsttuberculosis